Analyst Reco. Merck & Co., Inc.

Equities

MRK

US58933Y1055

Pharmaceuticals

Market Closed - Nyse Other stock markets 16:00:57 2026-05-20 EDT			5-day change	1st Jan Change
113.00 ^USD	-1.09%		-0.40%	+7.35%

05-20	National Advertising Review Board refers Merck animal health to FTC & FDA for Bravecto Quantum dosing claims	RE
05-20	Pharma sector doubles down on AI amid hopes of slashing costs, timelines	RE

Analyst Reco.

05-18	Regeneron drops after skin cancer treatment fails late-stage trial	RE
05-01	Goldman Sachs Adjusts Merck Price Target to $137 From $133	MT
05-01	Wells Fargo Adjusts Merck Price Target to $145 From $150	MT
05-01	Morgan Stanley Raises Price Target on Merck to $112 From $109, Keeps Equalweight Rating	MT
04-21	Arcus Biosciences Has Favorable Setup After Merck Belzutifan Failure, Wedbush Says	MT
04-21	Leerink Partners Cuts Merck Price Target to $127 From $129, Maintains Outperform Rating	MT
04-08	Wolfe Research Adjusts PT on Merck & Co. to $150 From $142, Maintains Outperform Rating	MT
04-06	JPMorgan Adjusts Price Target on Merck & Co. to $135 From $125, Maintains Overweight Rating	MT
03-31	Jefferies Adjusts Price Target on Merck & Co. to $138 From $132, Maintains Buy Rating	MT
03-19	Citigroup Adjusts Price Target on Merck & Co. to $125 From $120, Maintains Neutral Rating	MT
03-19	Jefferies Adjusts Price Target on Merck & Co. to $132 From $130, Maintains Buy Rating	MT
03-12	Wells Fargo Adjusts Price Target on Merck & Co. to $150 From $135, Maintains Overweight Rating	MT
03-03	Wolfe Adjusts Price Target on Merck to $142 From $135, Maintains Outperform Rating	MT
03-02	Leerink Partners Adjusts Price Target on Merck & Co to $129 From $128, Maintains Outperform Rating	MT
02-20	HSBC Adjusts Price Target on Merck to $135 From $120, Maintains Buy Rating	MT
02-20	Barclays Initiates Coverage on Merck With Overweight Rating	MT
02-13	Merck Shares Rise After Deutsche Bank Upgrade	MT
02-13	Deutsche Bank Upgrades Merck to Buy From Hold, Adjusts Price Target to $150 From $115	MT
02-13	Deutsche Bank Upgrades Merck to Buy From Hold, Adjusts Price Target to $150 From $115	MT
02-12	Argus Adjusts Price Target on Merck to $130 From $110, Maintains Buy Rating	MT
02-11	Daiwa Securities Adjusts PT on Merck & Co. to $120 From $86, Maintains Neutral Rating	MT
02-10	Rothschild & Co Redburn Adjusts Price Target on Merck & Co. to $140 From $135, Maintains Buy Rating	MT
02-06	Guggenheim Adjusts Price Target on Merck & Co to $140 From $122, Maintains Buy Rating	MT
02-04	Merck's Pipeline Progress and Business Development Strategy Remain in Focus, Morgan Stanley Says	MT
02-04	Bernstein Adjusts Price Target on Merck to $100 From $95, Maintains Market Perform Rating	MT